| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $59K | — | -33.2% |
| SG&A Expense | $2.1M | — | +41.8% |
| Operating Income | -$2.5M | — | +10.3% |
| Pre-tax Income | -$2.5M | — | +10.2% |
| Net Income | -$5.1M | — | -1.6% |
| EPS (Basic) | -$0.43 | — | +70.5% |
| EPS (Diluted) | -$0.43 | — | +70.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.7M | — | — |
| Current Assets | $6.6M | +258.6% | — |
| Total Assets | $7.7M | +44.9% | — |
| Current Liabilities | $3.1M | -15.3% | — |
| Total Liabilities | $3.1M | -33.2% | — |
| Stockholders' Equity | $4.6M | +615.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.7M | — | +31.3% |
| Capital Expenditures | $658 | — | -45.9% |
| Investing Cash Flow | -$651K | — | -228.5% |
| Financing Cash Flow | $7.3M | — | +2135.9% |
| Free Cash Flow | -$2.7M | — | +31.3% |